DuPont Superconductivity Team Achieves, Thanks To 'Networking'

In early 1987, when research team around the world began reporting higher and higher superconductivity temperatures, several scientists at E. I. du Pont de Nemours & Co in Wilmington, Del., were touched by the fervor spreading throughout the scientific community. It was the spontaneous outpouring of enthusiasm by this group of bench scientists—rather than a sudden profit-motivated decision on the part of DuPont senior management—that resulted shortly thereafter in the company’

Written byKenneth Friedman
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

And within a matter of months, the group had pulled off at least three major breakthroughs. These were made possible to a large extent by a refreshing show of corporate flexibility on the part of DuPont management—flexibility that permitted a kind of interdepartmental science networking not often seen in large-company environments.

Although DuPont has never been in the business of selling products that take advantage of superconductivity technology, the program that got underway last year was not its first foray into this field. In the mid-1960s, the company had launched an extensive effort pertaining to superconductors, a totally untargeted research project focusing on metal oxides and not aimed at any particular applications. By the mid- 1970s, however, progress had come to a standstill, the energy crisis had drawn many of DuPont’s scientists into what the company considered more important areas of research, and the project was nixed.

But the corporate ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies